Current Report Filing (8-k)
January 22 2018 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
January 22, 2018
CELGENE CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
001-34912
|
22-2711928
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
86 Morris Avenue, Summit, New Jersey
|
07901
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (908) 673-9000
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
¨
Item 7.01 Regulation FD Disclosure.
On January 22, 2018, Celgene Corporation (“Celgene”)
held an investor conference call relating to the execution of the Agreement and Plan of Merger (the “Merger Agreement”)
by and among Celgene, Blue Magpie Corporation, a wholly-owned subsidiary of Celgene (“Purchaser”), and Juno Therapeutics,
Inc. (“Juno”). Pursuant to the Merger Agreement, Purchaser will commence a tender offer to purchase all of the issued
and outstanding shares of Juno’s common stock, par value $0.0001 per share, for $87.00 per share in cash. If successful, the
tender offer will be followed by a merger of Purchaser with and into Juno, with Juno surviving the merger as a wholly-owned subsidiary
of Celgene. A copy of the presentation presented on the investor conference call is furnished herewith as Exhibit 99.1 and is incorporated
herein by reference.
On January 22, 2018, Celgene and Juno issued a joint press release
announcing the execution of the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated
herein by reference.
The information in Item 7.01 of this Form 8-K (including the exhibits
referenced herein) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be
deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
Important Information
The tender offer described herein has not yet commenced. The description
contained herein is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any shares
of Juno. At the time the tender offer is commenced, Celgene and Purchaser intend to file with the U.S. Securities and Exchange
Commission (the “SEC”) a Tender Offer Statement on Schedule TO containing an offer to purchase, a form of letter of
transmittal and other documents relating to the tender offer, and Juno intends to file a Solicitation/Recommendation Statement
on Schedule 14D-9 with respect to the tender offer. Celgene, Purchaser and Juno intend to mail these documents to the stockholders
of Juno. THESE DOCUMENTS, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WILL CONTAIN IMPORTANT INFORMATION ABOUT THE
TENDER OFFER AND JUNO STOCKHOLDERS ARE URGED TO READ THEM CAREFULLY WHEN THEY BECOME AVAILABLE. STOCKHOLDERS OF JUNO WILL BE ABLE
TO OBTAIN A FREE COPY OF THESE DOCUMENTS (WHEN THEY BECOME AVAILABLE) AND OTHER DOCUMENTS FILED BY JUNO, CELGENE OR PURCHASER WITH
THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,”
“anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,”
“outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions
and projections, and speak only as of the date they are made. Celgene undertakes no obligation to update any forward-looking statement
in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent
risks and uncertainties, most of which are difficult to predict and are generally beyond the control of Celgene, including the
following: (a) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger
Agreement; (b) the inability to complete the transaction due to the failure to satisfy conditions to the transaction; (c) the risk
that the proposed transaction disrupts current plans and operations; (d) difficulties or unanticipated expenses in connection with
integrating Juno into Celgene; (e) the risk that the acquisition does not perform as planned; and (f) potential difficulties in
employee retention following the closing of the transaction. Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail
in the public reports of each company filed with the SEC.
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
CELGENE CORPORATION
|
|
|
|
|
Date: January 22, 2018
|
|
By:
|
/s/ Peter N. Kellogg
|
|
|
|
Peter N. Kellogg
|
|
|
|
Executive Vice President and
|
|
|
|
Chief Financial Officer
(principal financial and accounting officer)
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024